Ashwagandha Under the Microscope: Efficacy, Dosing, and Formulation Insights

India — 24 May 2026

Ashwagandha, or Withania somnifera, is frequently touted as a panacea for stress and anxiety, its market penetration seemingly unstoppable. But does the science truly support the pervasive marketing claims? Are formulators investing in robust clinical efficacy, or merely chasing a trend fuelled by anecdotal enthusiasm and a compelling narrative? We often hear about its "adaptogenic" qualities, but what does the data actually reveal about its impact on cortisol levels and perceived stress?

What the Clinical Evidence Actually Shows

While a body of research supports ashwagandha's anxiolytic properties, the devil is often in the dosage and standardisation. Several human trials, notably a 2019 study published in Medicine (Baltimore) involving 60 participants, demonstrated a significant reduction in perceived stress and serum cortisol levels with 240 mg/day of a standardised ashwagandha extract over 60 days. Another pivotal 2012 trial by Chandrasekhar et al., published in the Indian Journal of Psychological Medicine, showed a 69.5% reduction in anxiety scores and a 27.9% decrease in serum cortisol in subjects receiving 300 mg of a high-concentration full-spectrum extract twice daily for 60 days. However, many studies employ proprietary extracts (e.g., KSM-66, Sensoril), which complicates direct comparisons and generalisability to generic raw materials. Limitations often include small sample sizes, short study durations, and potential conflicts of interest given the involvement of ingredient manufacturers. "The efficacy is often intrinsically linked to the specific extract and its withanolide content, which isn't always transparent in retail products," notes Dr. Anya Sharma, a pharmacognosy researcher.

The Formulation Reality

Formulating with ashwagandha presents distinct challenges beyond simply sourcing a powder. Bioavailability is a key concern; withanolides, the primary active compounds, are lipophilic and can exhibit poor absorption. Optimal forms typically involve standardised extracts with guaranteed percentages of specific withanolides (e.g., 5% withanolides by HPLC). The choice between root and leaf extracts also matters, as their phytochemical profiles differ. Excipient interactions, particularly with binders and fillers, must be carefully considered to ensure disintegration and dissolution. Shelf stability, especially concerning oxidation of active compounds, necessitates appropriate packaging and potentially antioxidant co-formulation. A common pitfall is using unstandardised raw material, which can lead to highly variable potency. "Without rigorous standardisation to key bioactive markers, formulators are essentially working blind, risking inconsistent product efficacy and consumer disappointment," states Mr. David Grant, Head of Product Development at NutraSol. Lead times for high-quality, certified organic extracts can extend to 12-16 weeks, impacting production schedules.

Market Position and Commercial Viability

The global ashwagandha market is projected to reach £1.5 billion by 2028, exhibiting a compound annual growth rate (CAGR) of approximately 14%. This growth trajectory suggests robust consumer demand, yet it also invites fierce competition and pricing pressures. Manufacturers must navigate minimum order quantities (MOQs) for branded extracts, often ranging from 50 kg to 200 kg, which can be prohibitive for smaller brands. Margin expectations are high, but raw material costs for premium, clinically validated extracts can be 5-10 times higher than unstandardised powders. A 240 mg dose of a high-quality extract might add £0.05-£0.10 to the cost of goods per capsule, demanding careful retail pricing strategies to maintain profitability. Brands must clearly articulate the value proposition of superior extracts to justify a higher price point in a crowded market.

What This Means for India

India, as the primary source and traditional home of ashwagandha, faces a unique set of opportunities and challenges. Regulatory oversight by bodies like AYUSH is evolving, but ensuring quality and preventing adulteration remains crucial for maintaining international trust. Domestic consumer demand for traditional Ayurvedic remedies, including ashwagandha, is robust and growing, driven by a renewed interest in natural health solutions. However, the competitive landscape is intense, with numerous local players offering a wide range of products, from raw powders to sophisticated extracts. Sustainable sourcing practices are becoming increasingly important, as overharvesting can threaten wild populations and impact long-term supply stability. Indian manufacturers have an advantage in supply chain control but must invest in rigorous quality control to meet international compliance standards.

The Bottom Line for Formulators

Formulators should invest in ashwagandha, but with discernment. Focus on clinically validated, standardised extracts with guaranteed withanolide content, ideally those used in robust human trials at effective dosages (e.g., 240-600 mg/day). Be prepared for higher raw material costs and longer lead times for premium ingredients. Avoid unstandardised bulk powders, which risk underdosing and erode consumer trust. The commercial viability hinges on differentiating through scientific backing, not just marketing hype.